Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
β-D-mannuronic acid for myelodysplastic syndrome
IRCT20130622013739N11Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing β-D-mannuronic acid + conventional drugs with Placebo + conventional drugs (2 arms). Primary endpoints: Average leukocyte count, Average hemoglobin level and 3 more. Started Jan 2018; status: completed.
02
Drugs
D-mannuronic acid
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on IRCT20130622013739N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130622013739N11.